Magnesium aspartate
Brand names: Magnaspartate
Magnesium aspartate is an oral magnesium salt used to treat or prevent magnesium deficiency and hypomagnesaemia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It supplies elemental magnesium, an essential cofactor for numerous enzymatic reactions and for neuromuscular and cardiac function, correcting a deficiency state.
Prescribing in practice
- Use with caution and reduced exposure in significant renal impairment, where magnesium can accumulate and cause hypermagnesaemia.
- Diarrhoea is the most common dose-limiting side effect of oral magnesium salts.
- Oral magnesium may reduce absorption of some drugs, such as certain antibiotics, so separate the timing of administration.
Monitoring
Monitor serum magnesium, and renal function where relevant, to confirm replacement and avoid accumulation.
Counselling the patient
- Take with food to reduce stomach upset.
- Loose stools may occur; report persistent diarrhoea.
- Separate from certain other medicines by an interval as advised.
Evidence & guidelines
Oral magnesium salts are standard, well-established therapy for correcting and preventing magnesium deficiency.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016